PUBLICATION IN THE MEN’S HEALTH MAGAZINE (ISSUE #3, NOVEMBER 2020)
#SYSTEMPHARMSCIENCE
Topic: “Evaluation of the effectiveness of the drug PHARMAPROST in monotherapy in patients with a combination of grade I benign prostatic hyperplasia and chronic abacterial prostatitis”
In this article, the author conducts research aimed at studying PHARMAPROST as monotherapy.
The results are impressive! The obtained data confirm the clinical efficacy of PHARMAPROST in patients with a combination of grade I BPH and chronic abacterial prostatitis (NIH USA, category IIIa CP/CPPS – chronic prostatitis/chronic pelvic pain syndrome with signs of inflammation). High clinical (89.6–91.7%) efficiency of PHARMAPROST application has been proven. The treatment was accompanied by good tolerance and minimal side effects.
You can read the article below and even save it to yourself.
⭐️⭐️⭐️ PHARMARPOST ARTICLE